Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1241-1260 of 1,694 trials

Cerebral Adrenoleukodystrophy: Leriglitazone Study

We are studying whether leriglitazone can improve survival and slow disease progression in adult males with cerebral adrenoleukodystrophy. Participants will receive either the medication or a placebo to compare effects.

Adrenoleukodystrophy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNeurology

Type 1 Diabetes: Verapamil Treatment for Children

We are studying whether oral Verapamil can help preserve insulin production in children recently diagnosed with Type 1 diabetes. The trial also looks at the safety and effectiveness of this treatment in managing blood sugar levels.

Type 1 Diabetes>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesDiabetologyEndocrinology

Exercise and Statin Use in Advanced Cancer Treatment

We are studying whether supervised exercise and atorvastatin can improve cancer treatment outcomes for patients with advanced breast, renal, ovarian, and prostate cancers. We also want to understand how these interventions affect patients' quality of life and experiences during treatment.

Metastatic Breast, Ovarian, Prostate, and Kidney Cancer≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncologyUrology

Recurrent Grade-4 Glioma: Bortezomib and Temozolomide Study

We are studying the safety and effectiveness of combining Bortezomib with Temozolomide for patients with recurrent grade-4 glioma. This research may help improve treatment options for this challenging condition.

Malignant Glioma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Eosinophilic Asthma: Benralizumab Treatment Study

We are studying how well benralizumab works and its safety for people with eosinophilic asthma who are not well-controlled on standard treatments. This trial compares it to increasing their current medication dose.

Eosinophilic Asthma1-2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyPulmonology

Ovarian Cancer: ZN-c3 and Niraparib Study

We are studying the safety and effectiveness of a new drug, ZN-c3, alone and with niraparib for patients with platinum-resistant ovarian cancer. This trial aims to find better treatment options for those who have limited choices.

Recurrent Ovarian Cancer>2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Desmoid Tumors: Nirogacestat Study for Women

We are studying how Nirogacestat affects ovarian function in adult premenopausal women with desmoid tumors. The trial aims to understand any ovarian toxicity and the overall safety of the treatment.

Desmoid Tumors (Aggressive Fibromatosis)1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Eosinophilic Esophagitis: Budesonide Dosing Study

We are comparing the effectiveness and tolerability of taking budesonide once daily versus twice daily for adults with esophagus inflammation. This study aims to see if both dosing schedules work equally well and how they affect patients' quality of life.

Eosinophilic EsophagitisConfirmation phase (III)≤5 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Myelofibrosis: Roginolisib with Ruxolitinib

We are studying the safety and tolerability of roginolisib combined with ruxolitinib for patients with myelofibrosis who haven't responded to other treatments. The trial also looks at symptom improvement and changes in spleen size.

MyelofibrosisSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Fecal Incontinence: Botulinum Toxin Injections

We are studying how botulinum toxin injections may improve rectal movement in patients with fecal incontinence. The trial will also look at the treatment's effectiveness, quality of life, and tolerance after one month.

Fecal Incontinence>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Acute Myeloid Leukemia: Venetoclax and Azacitidine Study

We are comparing a new treatment combination with standard chemotherapy for patients with newly diagnosed acute myeloid leukemia and NPM1 mutations. The goal is to see if this new approach is more effective and easier to tolerate.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Grass Allergy: Vitamin D Enhanced Immunotherapy

We are studying whether combining intralymphatic immunotherapy with vitamin D helps improve allergy symptoms in people with moderate to severe grass allergies during pollen season.

Allergic Rhinitis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesAllergology

Multiple Myeloma: New CAR-T Cell Therapy Study

We are testing a new CAR-T cell therapy for adults with relapsed or refractory multiple myeloma who have been treated with lenalidomide. The goal is to see if it works better than standard treatments currently available.

Relapsed/Refractory Multiple Myeloma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Oral Arsenic for Low-Risk Myelodysplastic Syndromes

We are studying whether oral arsenic can help patients with low-risk myelodysplastic syndromes who haven't responded to other treatments. The trial aims to assess its safety and effectiveness over 12 weeks.

Low-Risk Myelodysplastic Syndromes>2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Multiple Myeloma and Knee Surgery: Apixaban Study

We are comparing how the blood thinner Apixaban works in patients with newly diagnosed multiple myeloma and those undergoing knee replacement surgery. This study aims to understand its effects on blood clotting and how it behaves in the body.

Thromboembolism Prophylaxis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyHematologyOncology

Schizophrenia: Biomarkers for Clozapine Response

We are investigating whether specific biomarkers can help predict how well individuals with schizophrenia respond to clozapine. This research may lead to more tailored treatments for those who need them.

Schizophrenia≤3 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNeurologyPsychiatry

Hypertrophic Cardiomyopathy: Bisoprolol vs. Verapamil

We are studying the effects of Bisoprolol and Verapamil on symptoms and heart function in patients with non-obstructive hypertrophic cardiomyopathy. Our goal is to see if these treatments can improve exercise capacity and reduce heart rhythm issues.

Non-obstructive Hypertrophic Cardiomyopathy3-6 monthsMonitoring phase (IV)Standard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Steroid Treatment for Wheezing in Children

We are studying whether a new steroid treatment can help prevent asthma in children who wheezed for the first time after a rhinovirus infection. The trial will also look at the frequency and severity of wheezing episodes over time.

Acute Wheezing/Bronchiolitis1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

Heart Procedure: Single vs. Dual Antiplatelet Therapy

We are comparing a single medication to a combination of two medications for patients after a heart procedure. The goal is to see if the single medication is just as safe and effective while reducing bleeding risks.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Almagate for Heartburn in Pregnant Women

We are studying the safety of almagate for treating heartburn and reflux in pregnant women. The trial also examines how this treatment affects the health of the fetus and newborn.

Heartburn and Reflux>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyGynecology and Obstetrics